Adaptive Biotechnologies Corporation announced that clonoSEQ® is now available to health care providers as a fully integrated test in Aura, Epic?s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care. MRD refers to the number of cancer cells that might remain in a patient?s body during and after treatment and that may eventually lead to recurrence of the disease.

clonoSEQ is the only FDA-cleared test to detect MRD in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia. clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test. MRD is one of the strongest predictors of outcomes in blood cancers and routine testing provides a personalized way to track a patient?s individual response to treatment and inform clinical decision-making to optimize care.

Under the partnership established in September 2022, clonoSEQ is available to healthcare providers through Aura, Epic's specialty diagnostics suite. Integration with Epic EHR provides convenient access to clonoSEQ MRD results along with discrete data directly in patient records, enabling faster, more efficient decision-making for oncologists and equipping patients with real-time insights into their disease status.